Sources Used in Current Review
2019 review performed by Sarah E Wheeler PhD, FAACC, Assistant Professor University of Pittsburgh, Medical Director Automated Testing Laboratories UPMC Mercy, UPMC Children’s Hospital, Associate Medical Director Clinical Immunopathology UPMC Presbyterian, Shadyside, Magee Women’s Hospital.
Dieplinger B, Bocksrucker C, Egger M, Eggers C, Haltmayer M, Mueller T. Prognostic Value of Inflammatory and Cardiovascular Biomarkers for Prediction of 90-Day All-Cause Mortality after Acute Ischemic Stroke-Results from the Linz Stroke Unit Study. Clin Chem. 2017 Jun;63(6):1101-1109.
Akbari M, Hassan-Zadeh V. IL-6 signalling pathways and the development of type 2 diabetes. Inflammopharmacology. 2018 Jun;26(3):685-698.
Fan SL, Miller NS, Lee J, Remick DG. Diagnosing sepsis – The role of laboratory medicine. Clin Chim Acta. 2016 Sep 1;460:203-10.
Unver N, McAllister F. IL-6 family cytokines: Key inflammatory mediators as biomarkers and potential therapeutic targets. Cytokine Growth Factor Rev. 2018 Jun;41:10-17.
Vainer N, Dehlendorff C, Johansen JS. Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer. Oncotarget. 2018 Jul 3;9(51):29820-29841.
Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011 May;1813(5):878-88.
Kamimura D, Ishihara K, Hirano T. IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol. 2003;149:1-38.
Ibrahim NE, Januzzi JL Jr. Beyond Natriuretic Peptides for Diagnosis and Management of Heart Failure. Clin Chem. 2017 Jan;63(1):211-222.
Duprez DA, Otvos J, Sanchez OA, Mackey RH, Tracy R, Jacobs DR Jr. Comparison of the Predictive Value of GlycA and Other Biomarkers of Inflammation for Total Death, Incident Cardiovascular Events, Noncardiovascular and Noncancer Inflammatory-Related Events, and Total Cancer Events. Clin Chem. 2016 Jul;62(7):1020-31.
Sources Used in Previous Reviews
Lowe, G. et. al. (2014). Circulating Inflammatory Markers and the Risk of Vascular Complications and Mortality in People With Type 2 Diabetes and Cardiovascular Disease or Risk Factors: The ADVANCE Study Medscape Multispecialty from Diabetes. 2014;63(3):1115-1123. [On-line information]. Available online at https://www.medscape.com/viewarticle/821358. Accessed June 2014.
Genzen, J. (Updated 2014 May). Acute Phase Proteins – Acute Phase Reactants. ARUP Consult [On-line information]. Available online at https://www.arupconsult.com/Topics/AcutePhaseReactants.html?client_ID=LTD#tabs=0. Accessed June 2014.
Erta, M. et. al. (2012 October 25). Interleukin-6, a Major Cytokine in the Central Nervous System. Int J Biol Sci. 2012; 8(9): 1254–1266. [On-line information]. Available online at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491449/. Accessed June 2014.
Ferrari, R. et. al. (2013). Three-Year Follow-Up of Interleukin 6 and C-Reactive Protein in Chronic Obstructive Pulmonary Disease. Medscape Multispecialty from Respiratory Research. 2013;14(24) [On-line information]. Available online at https://www.medscape.com/viewarticle/804945. Accessed June 2014.
Check, W. (2011 March). Viewing inflammation, with markers new and old. CAP Today [On-line information]. Available online through https://www.cap.org. Accessed June 2014.
Kaptoge, S. et. al. (2014). Inflammatory Cytokines and Risk of Coronary Heart Disease New Prospective Study and Updated Meta-analysis. Medscape Multispecialty from Eur Heart J. 2014;35(9):578-589. [On-line information]. Available online at https://www.medscape.com/viewarticle/821753. Accessed June 2014.
Barnes, T. et. al. (2011 July). The Many Faces of Interleukin-6: The Role of IL-6 in Inflammation, Vasculopathy, and Fibrosis in Systemic Sclerosis. International Journal of Rheumatology Volume 2011, Article ID 721608 [On-line information]. Available online at https://www.hindawi.com/journals/ijr/2011/721608/. Accessed June 2014.
Scheller, J. and Rose-John, S. (2012 July 28). The interleukin 6 pathway and atherosclerosis. The Lancet, Volume 380, Issue 9839, p 338. [On-line information]. Available online at https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61246-X/fulltext. Accessed June 2014.
Kristiansen, O. and Mandrup-Poulsen, T. (2005 December). Interleukin-6 and Diabetes, The Good, the Bad, or the Indifferent? Diabetes, V 54 (2) [On-line information]. Available online at https://diabetes.diabetesjournals.org/content/54/suppl_2/S114.full. Accessed June 2014.
Lehman, C. and Meikle, A. W. (Updated 2013 September). Ischemic Heart Disease – IHD. ARUP Consult [On-line information]. Available online at https://www.arupconsult.com/Topics/IHD.html?client_ID=LTD#tabs=0. Accessed June 2014.
O’Reilly, S. et. al. (2013 April 12). Interleukin-6: a new therapeutic target in systemic sclerosis? Clinical & Translational Immunology (2013) 2, e4; doi:10.1038/cti.2013.2 [On-line information]. Available online at https://www.nature.com/cti/journal/v2/n4/full/cti20132a.html. Accessed June 2014.
Schellera, J. et. al. (2011 May). The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochimica et Biophysica Acta 1813 (2011) 878–888 [On-line information]. Available online at https://www.sciencedirect.com/science/article/pii/S0167488911000425. Accessed June 2014.
Lewis, R. (2013 September 16). Chronic Inflammation May Preclude Healthy Aging. Medscape Medical News [On-line information]. Available online at https://www.medscape.com/viewarticle/811107. Accessed June 2014.
Nainggolan, L. (2012 March 15). Gene Studies: IL-6 Pathway Has Causal Role in Heart Disease. Medscape Multispecialty [On-line information]. Available online at https://www.medscape.com/viewarticle/760285. Accessed June 2014.
Pagana, K. D. & Pagana, T. J. (© 2011). Mosby’s Diagnostic and Laboratory Test Reference 10th Edition: Mosby, Inc., Saint Louis, MO. Pp 348-349.
Clarke, W., Editor (© 2011). Contemporary Practice in Clinical Chemistry 2nd Edition: AACC Press, Washington, DC. Pp 489.